Display options
Cite
Sharma R. Data science-driven analyses of drugs inducing hypertension as an adverse effect. Mol Divers. 2020;25(2):801-810doi: 10.1007/s11030-020-10059-5.
Sharma, R. (2021). Data science-driven analyses of drugs inducing hypertension as an adverse effect. Molecular diversity, 25(2), 801-810. https://doi.org/10.1007/s11030-020-10059-5
Sharma, Reetu. "Data science-driven analyses of drugs inducing hypertension as an adverse effect." Molecular diversity vol. 25,2 (2021): 801-810. doi: https://doi.org/10.1007/s11030-020-10059-5
Sharma R. Data science-driven analyses of drugs inducing hypertension as an adverse effect. Mol Divers. 2021 May;25(2):801-810. doi: 10.1007/s11030-020-10059-5. Epub 2020 May 15. PMID: 32415493.
Copy Download .nbib Format: NLM
Share it on

Mol Divers. 2021 May;25(2):801-810. doi: 10.1007/s11030-020-10059-5. Epub 2020 May 15.

Data science-driven analyses of drugs inducing hypertension as an adverse effect.

Molecular diversity

Reetu Sharma

Affiliations

  1. CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, 500007, India. [email protected].

PMID: 32415493 DOI: 10.1007/s11030-020-10059-5

Abstract

The utilization of approved medication is a requisite to combat certain diseases for health; however, the undesirable adverse effects (AEs) due to medication are generally unavoidable. Hypertension is one of such AEs resulting from approved medication in which blood pressure in the arteries gets elevated and is a risk factor for several diseases including heart and kidney failure. HTs are the approved drugs that can cause hypertension as an AE. Here, the goal of the study is to investigate the structural and functional diversities of HTs. In our quest to unravel the structural parameters of the HTs, a systematic analysis of the HTs having a different number and type of ring systems was conducted. The cellular component, molecular function and biological processes adopted by the gene products were analyzed. Moreover, our systematically done analysis suggests that all the target families are active in a common pathway, that is, nerve transmission. A comparison of the selected structural and functional aspect of HTs with anti-hypertensives suggests that HTs follow certain structural and functional features in spite of many possibilities. Our study provides a promising methodology that considers the influence of structural diversity of AE causing agents on a functional perspective for precursory clinical decision making. This could be extended to explore the structural and functional trends that are adopted by agents causing certain diseases or AEs.

Keywords: Adverse effect; Approved drugs; Data science; Hypertension

References

  1. Lewis PR, Karpa KD, Felix TM (2015) Adverse effects of common drugs: adults. FP Essent 436:23–30 - PubMed
  2. Cheng F, Kovács IA, Barabási A-L (2019) Network-based prediction of drug combinations. Nat Commun 10(1):1197 - PubMed
  3. Lipinski C, Hopkins A (2004) Navigating chemical space for biology and medicine. Nature 432(7019):855–861 - PubMed
  4. Clemons PA, Wilson JA, Dančík V, Muller S, Carrinski HA, Wagner BK, Koehler AN, Schreiber SL (2011) Quantifying structure and performance diversity for sets of small molecules comprising small-molecule screening collections. Proc Natl Acad Sci USA 108(17):6817–6822 - PubMed
  5. Clemons PA, Bodycombe NE, Carrinski HA, Wilson JA, Shamji AF, Wagner BK, Koehler AN, Schreiber SL (2010) Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles. Proc Natl Acad Sci USA 107(44):18787–18792 - PubMed
  6. Barabási A-L, Gulbahce N, Loscalzo J (2011) Network medicine: a network-based approach to human disease. Nat Rev Genet 12(1):56–68 - PubMed
  7. Medina-Franco JL, Giulianotti MA, Welmaker GS, Houghten RA (2013) Shifting from the single- to the multitarget paradigm in drug discovery. Drug Discov Today 18:495–501 - PubMed
  8. Medina-Franco JL (2012) Interrogating novel areas of chemical space for drug discovery using chemoinformatics. Drug Dev Res 73(7):430–438 - PubMed
  9. Brown N, Jacoby E (2006) On scaffolds and hopping in medicinal chemistry. Mini-Rev Med Chem 6(11):1217–1229 - PubMed
  10. Shang J, Sun H, Liu H, Chen F, Tian S, Pan P, Li D, Kong D, Hou T (2017) Comparative analyses of structural features and scaffold diversity for purchasable compound libraries. J Cheminform 9:25–40 - PubMed
  11. Welsch ME, Snyder SA, Stockwell BR (2010) Privileged scaffolds for library design and drug discovery. Curr Opin Chem Biol 14(3):347–361 - PubMed
  12. Bemis GW, Murcko MA (1996) The properties of known drugs. J Med Chem 39(15):2887–2893 - PubMed
  13. Sharma AK, Srivastava GN, Roy A, Sharma VK (2017) ToxiM: a toxicity prediction tool for small molecules developed using machine learning and chemoinformatics approaches. Front Pharmacol 8:880–897 - PubMed
  14. Limban C, Nuţă DC, Chiriţă C, Negreș S, Arsene AL, Goumenou M, Karakitsios SP, Tsatsakis AM, Sarigiannis DA (2018) The use of structural alerts to avoid the toxicity of pharmaceuticals. Toxicol Rep 5:943–953 - PubMed
  15. Alves V, Muratov E, Capuzzi S, Politi R, Low Y, Braga R, Zakharov AV, Sedykh A, Mokshyna E, Farag S et al (2016) Alarms about structural alerts. Green Chem 18(16):4348–4360 - PubMed
  16. Beck KR, Thompson GR, Odermatt A (2019) Drug-induced endocrine blood pressure elevation. Pharmacol Res 154:104311 - PubMed
  17. Rubio-Guerra AF, Rodriguez-Lopez L, Vargas-Ayala G, Huerta-Ramirez S, Serna DC, Lozano-Nuevo JJ (2013) Depression increases the risk for uncontrolled hypertension. Exp Clin Cardiol 18(1):10–12 - PubMed
  18. Li Z, Li Y, Chen L, Chen P, Hu Y (2015) Prevalence of depression in patients with hypertension. Medicine (Baltimore) 94(31):1317–1322 - PubMed
  19. Ancker OV, Wehland M, Bauer J, Infanger M, Grimm D (2017) The adverse effect of hypertension in the treatment of thyroid cancer with multi-kinase inhibitors. Int J Mol Sci 18(3):625–743 - PubMed
  20. Barton M, Prossnitz ER, Meyer MR (2012) Testosterone and secondary hypertension: new pieces to the puzzle. Hypertension 59(6):1101–1103 - PubMed
  21. van Amsterdam J, Opperhuizen A, Hartgens F (2010) Adverse health effects of anabolic-androgenic steroids. Regul Toxicol Pharmacol 57(1):117–123 - PubMed
  22. Chen S-Y, Fan S-Z, Chen L-K (2013) Ultralow dose combined spinal–epidural anesthesia for cesarean section in ritodrine-related severe pulmonary hypertension. Taiwan J Obstet Gynecol 52(4):617 - PubMed
  23. Spiekerkoetter E, Fabel H, Hoeper MM (2002) Effects of inhaled salbutamol in primary pulmonary hypertension. Eur Respir J 20(3):524–528 - PubMed
  24. Oskarsson A, Ullerås E, Ohlsson Andersson Å (2016) Acetaminophen Increases Aldosterone Secretion While Suppressing Cortisol and Androgens: a Possible Link to Increased Risk of Hypertension. Am J Hypertens 29(10):1158–1164 - PubMed
  25. Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, Maciejewski A, Arndt D, Wilson M, Neveu V et al (2014) DrugBank 4.0: shedding new light on drug metabolism. Nucl Acids Res 42:D1091–D1097 - PubMed
  26. The UniProt Consortium (2017) UniProt: the universal protein knowledgebase. Nucl Acids Res 45(D1):D158–D169 - PubMed
  27. Hammer Ø, Harper DAT, Ryan PD (2001) PAST: paleontological statistics software package for education and data analysis. Palaeontologia Electronica 4(1):9 - PubMed
  28. Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6(11):881–890 - PubMed
  29. Siegel MG, Vieth M (2007) Drugs in other drugs: a new look at drugs as fragments. Drug Discov Today 12(1–2):71–79 - PubMed
  30. Dalvie D, Nair S, Kang P, Loi C-M (2010) Chapter 6: Influence of aromatic rings on ADME properties of drugs. In: metabolism, pharmacokinetics and toxicity of functional groups. The royal society of chemistry, pp 275–327 - PubMed
  31. Worley JD (1993) Heterocyclic chemistry, second edition (Gilchrist, T.L.). J Chem Educ 70(3):A89 - PubMed
  32. Adriani J, Yarbrough WM (1972) Drugs containing halogen atoms: toxicity and lack of toxicity. J Med Assoc Georgia 61(10):347–351 - PubMed
  33. Hernandes MZ, Cavalcanti SMT, Moreira DRM, de Azevedo Junior WF, Leite ACL (2010) Halogen atoms in the modern medicinal chemistry: hints for the drug design. Curr Drug Targets 11(3):303–314 - PubMed
  34. Benarroch EE (2011) Na+, K+-ATPase: functions in the nervous system and involvement in neurologic disease. Neurology 76(3):287–293 - PubMed
  35. Nikolic LM (2016) Regulation of Na+/K+-ATPase activity in the nervous system. In: Dhalla NS, Chakraborti S (eds) Regulation of membrane Na+-K+ATPase. Springer, Cham, pp 295–309 - PubMed
  36. Shih JC, Chen K, Ridd MJ (1999) Role of MAO A and B in neurotransmitter metabolism and behavior. Pol J Pharmacol 51(1):25–29 - PubMed
  37. Kim Y-B, Kim Yoon S, Kim Woong B, Shen F-Y, Lee Seung W, Chung Hyun J, Kim Jeong S, Han Hee C, Colwell Christopher S, Kim Yang I (2013) GABAergic excitation of vasopressin neurons. Circ Res 113(12):1296–1307 - PubMed
  38. Zomot E, Bendahan A, Quick M, Zhao Y, Javitch JA, Kanner BI (2007) Mechanism of chloride interaction with neurotransmitter: sodium symporters. Nature 449:726 - PubMed
  39. Czapski GA, Czubowicz K, Strosznajder JB, Strosznajder RP (2016) The Lipoxygenases: their regulation and implication in alzheimer’s disease. Neurochem Res 41:243–257 - PubMed
  40. Li Y, Maher P, Schubert D (1997) A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron 19(2):453–463 - PubMed
  41. Yan N (2015) Structural biology of the major facilitator superfamily transporters. Annu Rev Biophys 44(1):257–283 - PubMed
  42. Olivares AM, Moreno-Ramos OA, Haider NB (2016) Role of nuclear receptors in central nervous system development and associated diseases. J Exp Neurosci 9(Suppl 2):93–121 - PubMed
  43. Manville RW, Papanikolaou M, Abbott GW (2018) Direct neurotransmitter activation of voltage-gated potassium channels. Nat Commun 9(1):1847 - PubMed
  44. Coceani F (1974) Prostaglandins and the central nervous system. JAMA Internal Med 133(1):119–129 - PubMed
  45. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62(3):405–496 - PubMed
  46. Siddiqi N, Shatat IF (2019) Antihypertensive agents: a long way to safe drug prescribing in children. Pediatr Nephrol 7:4314–4330 - PubMed
  47. Roush GC, Sica DA (2016) Diuretics for hypertension: a review and update. Am J Hypertens 29(10):1130–1137 - PubMed
  48. Savitha MN, Suvilesh KN, Siddesha JM, Gowda M, Choudhury M, Velmurugan D, Umashankar M, Vishwanath BS (2019) Combinatorial inhibition of angiotensin converting enyme, neutral endopeptidase and aminopeptidase n by n-methylated peptides alleviates blood pressure and fibrosis in rat model of dexamethasone-induced hypertension. Peptides 123:170180 - PubMed
  49. Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GWK, Wright JM (2015) First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev 1:CD008170 - PubMed
  50. Li C, Yan X, Wu D, Zhang K, Liang X, Pan Y, Zhou Y, Chen F, Chen X, Yang S et al (2019) Vaccine targeted alpha 1d-adrenergic receptor for hypertension. Hypertension 74(6):1551–1562 - PubMed
  51. Zablotskaya A, Segal I, Geronikaki A, Shestakova I, Nikolajeva V, Makarenkova G (2017) N-Heterocyclic choline analogues based on 1,2,3,4-tetrahydro(iso)quinoline scaffold with anticancer and anti-infective dual action. Pharmacol Rep 69(3):575–581 - PubMed
  52. Solomon VR, Lee H (2011) Quinoline as a privileged scaffold in cancer drug discovery. Curr Med Chem 18(10):1488–1508 - PubMed
  53. Mishra AP, Bajpai A, Rai AK (2019) 1,4-Dihydropyridine: a dependable heterocyclic ring with the promising and the most anticipable therapeutic effects. Mini Rev Med Chem 19(15):1219–1254 - PubMed

Substances

MeSH terms

Publication Types

Grant support